On October 9, 2025, a panel from the Ninth Circuit Court of Appeals heard arguments from insurers and health plans challenging a lower court’s dismissal of their antitrust claims against Gilead Sciences. The plaintiffs contend that Gilead engaged in a “product-hop” strategy to extend its market exclusivity for HIV medications and allege an agreement with Teva Pharmaceuticals to delay the entry of generic alternatives.
The insurers argue that the district court erred in dismissing their claims before trial, particularly by not considering the absence of a price reduction as indicative of a potential agreement between Gilead and Teva to postpone generic competition. This appeal underscores the ongoing legal scrutiny over pharmaceutical practices that may impede the availability of more affordable generic drugs.
Gilead has faced multiple legal challenges concerning its HIV drug portfolio. In June 2023, a jury in the U.S. District Court for the Northern District of California ruled in favor of Gilead, determining that a 2014 patent settlement with Teva did not violate antitrust laws and was not a reverse payment. The verdict affirmed that the settlement promoted competition by allowing earlier access to generic versions of Atripla and Truvada before the expiration of Gilead’s patents. ([gilead.com](https://www.gilead.com/company/company-statements/2023/gilead-prevails-in-hiv-antitrust-trial?utm_source=openai))
In a separate development, Gilead agreed to a $246.75 million settlement in October 2023 to resolve allegations that it employed anticompetitive practices to delay the market entry of generic HIV drugs. This settlement, approved by U.S. Senior District Judge Edward Chen, addressed claims that Gilead’s actions led to higher costs for consumers who purchased Truvada, Atripla, or their generic equivalents during a specified period. ([news.bloomberglaw.com](https://news.bloomberglaw.com/litigation/gilead-247-million-antitrust-deal-over-hiv-drugs-gets-final-nod?utm_source=openai))
Additionally, in January 2025, Gilead reached a settlement with the U.S. Department of Justice and the Department of Health and Human Services, concluding a five-year litigation over patents related to its HIV prevention drugs, Truvada and Descovy. The settlement followed a federal jury’s unanimous verdict in May 2023, which found the government’s patents invalid and determined that the government had breached multiple contracts with Gilead concerning PrEP research. ([gilead.com](https://www.gilead.com/company/company-statements/2025/gilead-statement-on-successful-resolution-with-us-department-of-justice-and-the-department-of-health-and-human-services-on-patents?utm_source=openai))
These legal proceedings highlight the complex interplay between pharmaceutical companies’ efforts to protect their intellectual property and the imperative to ensure timely access to affordable medications. The Ninth Circuit’s forthcoming decision in the current appeal will be closely watched for its potential impact on the pharmaceutical industry’s competitive practices and the availability of generic drugs.